WHY NOW?Currently, non-white groups comprise 36% of the total US population but only 15-20% of clinical trial participants collectively. Across research, racial and ethnic minorities are <2x underrepresented. The vast majority of literature quantifies the depth of the problem and its root causes, without much discussion of how individual players can change the status quo.We noticed an opportunity to go beyond the analysis and collect the tactical solutions that are being implemented today. Individual companies, sites, and researchers are making progress on an independent scale – the next step is to spread those efforts across the industry.
THE WHITE PAPERWe split the tactics into 5 lenses, grouped by granularity, from individual site-level opportunities to industry-wide topics. For each lens, we break down historic structural barriers and propose tactical solutions with real examples being implemented by researchers today.Here are the 5 lenses:1. Recruitment strategies and participant outreach. How we find and engage representative participants around existing sites.2. Site personnel and operations. How we hire and train site staff to lead the charge on diverse recruitment.3. Site selection. How we find, select, and manage research sites to support diverse participants.4. Trial protocol design. How we identify historically exclusionary criteria and make protocol amendments to improve accessibility.5. Regulation and economic incentives. How industry-wide incentive structures can influence change at scale.
WHO IS THIS WHITE PAPER FOR?If you work in or around clinical research and strive to improve representation in trials, this White Paper is for you. Strategies and solutions encompass every level of trial rollout, from protocol design to site operations and recruitment.